Transcode Therapeutics Inc (RNAZ)
TransCode Therapeutics Inc. is a NASDAQ-listed common stock company in the healthcare sector that focuses on biopharmaceutical development for cancer. The company is working on therapeutics and diagnostics aimed at treating and identifying cancer, with its lead candidate, TTX-MC138, designed to target microRNA-10b, a regulator associated with metastatic cancer cell survival. Its preclinical pipeline includes TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, along with two indication-agnostic programs. Additional programs include TTX-RIGA, which is based on RNA technology and targets innate immune activation in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based platform for editing cancer-causing genes within tumor cells; and TTX-mRNA, an mRNA platform intended to support cancer vaccine development. The company also has a strategic collaboration with The University of Texas M. D. Anderson Cancer Center and was incorporated in 2016. It is headquartered in Boston, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RNAZ
|
$8.55
|
2.6% Upside
|
Fair
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-0.2x
|
6.3x
|
—
|
8.296 M
|
138.4 M
|
0.0%
|
91.1%
|
-12.8
|
—
|
49.0%
|
